Decoding Pfizer’s Portfolio: A New Model for Precision in Pharma Investments

In the ever-evolving landscape of the biotech and pharmaceutical sectors, accurate valuation of post-revenue drug assets stands as the linchpin for informed and strategic decision-making. The significance of this valuation extends beyond the boardrooms of pharmaceutical companies to encompass venture capitalists, private equity firms, and regulatory bodies. In this blog post, we delve into the […] Source